• 1
    Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000; 50: 733
  • 2
    Huggins C, Hodges CV. Studies on prostate cancer I. The effect of castration, of estrogen and of androgen injection on the normal and on the hyperplastic glands of dogs. Cancer Res 1941; 1: 2938
  • 3
    Roth JA, Cristiano RJ. Gene therapy for cancer. what have we done and where are we going. J Natl Cancer Inst 1997; 89: 2139
  • 4
    Ko SC, Gotoh A, Thalmann G et al. Molecular therapy with recombinant p53 adenovirus in an androgen-independent metastatic huuman prostate cancer model. Human Gene Ther 1996; 7: 168391
  • 5
    Gotoh A, Kao C, Ko SC, Hamada K, Liu T-J, Chung LWK. Cytotoxic effects of recombinant adenovirus p53 and cell cycle regulator genes (p21WAF1/CIP1 and p16CDKN4) in human prostate cancers. J Urol 1997; 158: 63641
  • 6
    Swisher SG, Roth JA, Nemunaitis J et al. Adenoviral-mediated gene transfer in advanced non-small cell lung cancer. J Natl Cancer Inst 1999; 91: 76371
  • 7
    Clayman GL, El-Naggar AK, Lippman SM et al. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 1998; 16: 222132
  • 8
    Sandig V, Brand K, Herwig S, Lulas J, Bartek J, Strauss M. Adenovirally transferred p16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nature Med 1997; 3: 3139
  • 9
    El-Deiry WS, Tokino T, Velculescu VE et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 81725
  • 10
    Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 cdk-interacting protein Cip1 is a protein inhibitor of G1 cyclin-dependent kinase. Cell 1993; 75: 80516
  • 11
    Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 1994; 211: 908
  • 12
    Hunter T. Braking the cell cycle. Cell 1993; 75: 83941
  • 13
    Sherr CJ. G1 phase progression. cycling on cue. Cell 1994; 79: 5515
  • 14
    Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinase. Nature (London) 1993; 366: 7014
  • 15
    Kamb A. Cell-cycle regulators and cancer. T I G 1995; 11: 13640
  • 16
    Eastham JA, Hall SJ, Sehgal I et al. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res 1995; 55: 51515
  • 17
    Gotoh A, Mizuno Y, Okada H et al. Therapeutic effect of CDDP and VP-16 against human bladder cancers. In Vivo 1995; 9: 2637
  • 18
    Easthan JA, Grafton W, Martin LM, Williams BJ. Suppression of primary tumor growth and the progression to metastasis with p53 adenovirus in human prostate cancer. J Urol 2000; 164: 8149
  • 19
    Bookstein R, MacGrogan D, Hilsenbeck SG. P53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 1993; 53: 336973
  • 20
    Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature (London) 1994; 369: 5747
  • 21
    Macleiod KF, Sherry N, Hannon G et al. P53-dependent and independent expression of p21 during cell growth differentiation, and DNA damage. Genes Dev 1995; 9: 93544
  • 22
    Zhang W, Grasso L, Maclain CD et al. P53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation. Cancer Res 1995; 55: 66874
  • 23
    Zhang W-W, Fang X, Mazur W, French BA, Georges RN, Roth JA. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther 1994; 1: 513